Neximmune announces publication in frontiers in medicine highlighting the company's aim platform to treat viral diseases

Gaithersburg, md., jan. 18, 2023 (globe newswire) -- neximmune, inc. (nasdaq: nexi), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells, today announced the publication of an article highlighting the company's aim platform as a new immunotherapy approach for viral diseases in frontiers in medicine. the article, titled “aim platform: a new immunotherapy approach for viral diseases,” focuses on the ability of aim nanoparticles, which direct t cell response by mimicking the dendritic cell function, to consistently expand t cell populations with effector memory, central memory and self-renewing stem like memory phenotype directed at peptide-antigens from epstein-barr virus (ebv), human t-lymphotropic virus type 1 (htlv-1) and human papillomavirus (hpv). furthermore, t cells generated with the aim platform are highly polyfunctional and display substantial in vitro cytotoxic activity against respective targeted antigens.
NEXI Ratings Summary
NEXI Quant Ranking